DexCom, Inc. (0A4M.L)

131,96 +1,35 (+1,04%) In data: 06:57PM BST. Mercato aperto.

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 9.500

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Kevin Ronald Sayer	Executive Chairman, CEO & President	2,22M	N/D	1958
Mr. Jereme M. Sylvain	Executive VP, CFO & Chief Accounting Officer	841,14k	N/D	1980
Mr. Jacob Steven Leach	Executive VP & COO	994,13k	N/D	1978
Mr. Girish Naganathan	Executive VP & CTO	423,92k	N/D	1977
Mr. Michael Jon Brown	Executive VP & Chief Legal Officer	954,46k	N/D	1970
Mr. Shelly Ramasamy Selvaraj	Senior VP & Chief Information Officer	N/D	N/D	1959
Mr. Sean Christensen	Director of Corporate Affairs & Head of Investor Relations	N/D	N/D	N/D
Mr. Matthew Dolan	Executive Vice President of Strategy, Corporate Development & Dexcom Labs	N/D	N/D	1981
Ms. Leverne Marsh	Executive Vice President of Marketing	N/D	N/D	N/D
Ms. Sadie M. Stern	Executive VP & Chief Human Resources Officer	N/D	N/D	1975

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di DexCom, Inc. al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 9; diritti degli azionisti: 6; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.